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Background/Aims: We investigated changes in recurrence rates and significant recurrence pre-
dictors over time after complete cure of hepatocellular carcinoma (HCC). 
Methods: A total of 1,491 patients with first-time diagnosis of Barcelona Clinic Liver Cancer stage 
A HCC, completely cured by treatment between 2007 and 2016, were recruited from two Korean 
tertiary institutes. 
Results: The mean age of the population (1,144 men and 347 women) was 58.6 years. Of the 
total population, 914 patients (61.3%) had liver cirrhosis. Nine-hundred and forty-one (63.1%) 
and 550 (36.9%) patients were treated with surgical resection and radiofrequency ablation (RFA), 
respectively. One-year cumulative incidences of HCC recurrence were 14.3%, 9.9%, and 5.1% 
from the time of treatment, 3 years after treatment, and 5 years after treatment, respectively. 
Upon multivariate analysis, multiple tumors, maximal tumor size ≥3 cm, and high Model for End-
Stage Liver Disease scores were independently associated with increased HCC recurrence risk 
from the time of treatment and 1 and 2 years after curative treatment (all p<0.05, except for maxi-
mal tumor size ≥3 cm for recurrence 2 years after treatment). Meanwhile, liver cirrhosis and RFA 
were independently associated with the increased HCC recurrence risk for almost all time points 
(liver cirrhosis: all p<0.05; RFA: all p<0.005 except for recurrence from 5 years after treatment). 
Conclusions: The recurrence rate of HCC after curative treatment gradually decreased over 
time. Two years after treatment, when tumor-related factors lose their prognostic implications, 
may be used as a cutoff to define the boundary between early and late recurrence of HCC. (Gut 
Liver 2021;15:420-429)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most com-
mon tumor and second most common cause of cancer-
related death globally.1 In patients with Barcelona Clinic 
Liver Cancer (BCLC) stage A HCC, surgical resection 
or radiofrequency ablation (RFA) are usually recom-
mended.2-4 Though median survival reaches 50% to 70% 
at 5 years after curative treatment, recurrence rate  is still 
high.5-7 Because recurrence is the main cause of mortality 
in HCC patients,8,9 identification of recurrence patterns 
and predictive factors is crucial.
Previous studies have suggested two distinct types of 
HCC recurrence: tumors originating from subclinical 
metastasis of primary tumors and multicentric second 
primary tumor arising from diseased liver,10,11 so called 
“early” and “late” recurrence, respectively.12 Because each 
recurrence is based on different biology, this difference has 
to be accounted for establishing surveillance and treatment 
strategy for HCC recurrence.13 
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However, the lack of reliable markers applicable in clini-
cal setting makes it difficult to differentiate these recur-
rence types. Early recurrence is thought to be associated 
with tumor-related factors, and late recurrence with the 
liver disease-related factors. Previous studies assessed the 
prognostic implications of various risk factors with respect 
to early and late HCC recurrence. However, those stud-
ies have shown conflicting results.12,14-18 These disparities 
might be due to heterogeneous study population having 
various clinicopathological characteristics. In addition, the 
change of recurrence rates after curative treatment has also 
not been well assessed in previous studies, possibly arous-
ing confusion in establishing surveillance strategy for HCC 
recurrence.19
To counteract these shortcomings, we conducted this 
large, multicenter retrospective cohort study in patients 
with first-time diagnosis of BCLC A HCC who were com-
pletely cured with surgical resection or RFA. We investigat-
ed changes in recurrence rates and independent predictors 
of HCC recurrence over time after curative treatment.
MATERIALS AND METHODS
1. Study design and subjects
We retrospectively reviewed medical records of 4,487 
patients with first-time diagnosis of HCC at Korea Univer-
sity Anam Hospital and Yonsei University Severance Hos-
pital between 2007 and 2016. In total, 1,491 patients with 
BCLC stage A HCC, who were completely cured with sur-
gical resection or RFA were considered eligible. Exclusion 
criteria were: (1) previous history of treatment for HCC; 
(2) not treated or treated with methods other than surgical 
resection or RFA; (3) Child-Pugh class B and C; (4) East-
ern Cooperative Oncology Group performance status >2; 
(5) presence of extrahepatic metastasis; and (6) combined 
malignancy other than HCC. 
Flowsheet of all included patients is presented in Fig. 1. 
Patients with chronic hepatitis B virus (HBV) or hepatitis 
C virus (HCV) infection were treated for viral hepatitis as 
per treatment guidelines.20-23 
The study protocol was in accordance with the Declara-
tion of Helsinki guidelines. The need for written informed 
consent was waived because of the retrospective nature of 
this study. The study procedure was approved by the In-
stitutional Review Boards of Korea University Anam Hos-
2,665 Patients were excluded
933 BCLC stage B
1,211 BCLC stage C
521 BCLC stage D
331 Patients were excluded
76 No treatment for HCC
255 Other treatment
262 Patients were excluded
209 HCC recurrence
51 Lost to follow-up or death
278 Patients were excluded
205 HCC recurrence
73 Lost to follow-up or death




Lost to follow-up or death
152 Patients were excluded
66 HCC recurrence
86 Lost to follow-up or death
141 Patients were excluded
46 HCC recurrence
95 Lost to follow-up or death
1,491 Patients with BCLC stage A HCC and treated with
surgical resection or RFA
4,487 Patients who were first diagnosed as HCC
1,822 Patients with BCLC stage A HCC
1,229 Patients without HCC recurrence within 1 year
951 Patients without HCC recurrence within 2 years
710 Patients without HCC recurrence within 3 years
558 Patients without HCC recurrence within 4 years
417 Patients without HCC recurrence within 5 years
Fig. 1. Flowchart of the patient popu-
lation. 
HCC, hepatocellular carcinoma; BCLC, 
Barcelona Clinic Liver Cancer; RFA, 
radiofrequency ablation.
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pital and Yonsei University Health System (IRB number: 
2016AN0362).
2. Diagnosis and staging
Diagnosis of HCC was based on noninvasive criteria 
and/or pathology in cirrhotic patients, and pathology in 
non-cirrhotic patients. Noninvasive criteria were based on 
identification of typical hallmarks of HCC, obtained by 
multiphasic computed tomography (CT) or multiphase 
magnetic resonance imaging.24 BCLC staging system was 
used for staging HCC.25 
3. Curative treatment and evaluation of treatment 
response
Type of treatment (surgical resection vs RFA) was de-
termined according to the clinician’s decision based on the 
clinical practice guideline for HCC in Korea.2,26
Treatment response after curative treatment was evalu-
ated at 1 month after treatment. Complete response was 
defined as disappearance of any intratumoral arterial en-
hancement in all target lesions, as evaluated by multiphasic 
CT or magnetic resonance imaging at 1 month after treat-
ment.27
4. Recurrence surveillance after curative treatment
After curative treatment, patients were surveilled peri-
odically at outpatient clinics. Surveillance for recurrence 
consisted of imaging techniques by multiphasic CT or 
magnetic resonance imaging and blood tests including 
known predictors of HCC recurrence. Due to a lack of evi-
dence-based guidelines for recurrence surveillance, screen-
ing was conducted every 1 to 6 months as determined by 
the clinician’s decision.
Intrahepatic HCC recurrence was defined by the same 
diagnostic criteria applied for initial diagnosis. Extrahepat-
ic recurrence was evaluated by CT or bone scan performed 
at the discretion of the clinician. 
5. Data collection and primary endpoint assessment
We investigated patients’ age, gender, number of tumors, 
maximal tumor size, international normalized ratio, serum 
bilirubin, creatinine, alpha-fetoprotein (AFP), and protein 
induced by vitamin K absence or antagonist II (PIVKA-II) 
levels at the time of HCC diagnosis. The etiology of liver 
disease were classified as HBV, HCV, alcoholic liver disease 
and nonalcoholic fatty liver disease, based on serum hepa-
titis B surface antigen, hepatitis C antibody, imaging stud-
ies, and clinical history. 
6. Outcomes
Primary outcome was the change in HCC recurrence 
rate. Secondary outcome was the change of independent 
predictors for HCC recurrence over time after curative 
treatment. To analyze the change in recurrence rate and 
predictors of HCC recurrence, we performed different 
statistical analyses from previous studies, annually censor-
ing patients who developed recurrence and those lost to 
follow-up and death at the time of each event. Variables at 
the time of treatment were analyzed in total patients for 
rate and independent predictors of HCC recurrence from 
the time of treatment. Then, these analyses were repeated 
separately after annual exclusion of censored patients as 
follows; in remaining patients without censoring at each 
time points (1, 2, 3, 4, and 5 years after curative treatment), 
variables measured at each time point were analyzed for 
rate and independent predictors of HCC recurrence from 
each time point, respectively (Fig. 1). 
7. Statistical analysis
Data are expressed as means±standard deviation or 
numbers (%), as appropriate. The significance of differ-
ences among continuous and categorical variables was 
examined using the Student t-test and chi-square test, 
respectively. Cumulative incidence of HCC recurrence 
was evaluated by the Kaplan–Meier method. Multivariate 
analysis was performed to identify independent predictors 
of HCC recurrence using the Cox proportional hazards 
model.
Statistical analyses were conducted using Statistical 
Analysis Systems version 9.2 (SAS Institute Inc., Cary, NC, 
USA) and R software V.3.0 (R Foundation for Statistical 
Computing, Vienna, Austria; http://cran.r-project.org/). 
Two-sided p-values <0.05 were considered indicative of 
statistical significance.
RESULTS
1. Baseline characteristics of the study population
In total, 1,491 patients who were cured of BCLC stage A 
HCC through surgical resection or RFA were finally select-
ed for the statistical analysis (Fig. 1). The baseline character-
istics of the study population are listed in Table 1. The mean 
age was 58.6 years, and men were predominant (n=1,144, 
76.7%). In the study population, chronic HBV infection 
was the most frequent underlying liver disease (n=1,152, 
77.3%) followed by chronic HCV infection (n=137, 9.2%). 
Of the total population, 914 patients (61.3%) had liver 
cirrhosis. The mean number of tumors and mean size of 
maximal tumor were 1.1 and 2.8 cm, respectively. Serum 
AFP and PIVKA-II levels were 1.3±0.9 log10 ng/mL and 
1.8±0.7 log10 mAU/mL, respectively.
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2. Comparison between patients treated with surgical 
resection and RFA
Among all the patients, 941 (63.1%) were treated with 
surgical resection and 550 (36.9%) with RFA. As compared 
to patients treated with RFA, those treated with surgical 
resection had significantly younger age (mean 57.4 years 
vs 60.7 years, p<0.001), lower MELD score (mean 7.0 vs 
8.6, p<0.001), higher proportion of men (79.4% vs 72.2%, 
p=0.001), higher prevalence of HBV infection (82.8% 
vs 67.8%, p<0.001), lower prevalence of HCV infection 
(5.2% vs 16.0%, p<0.001), lower prevalence of alcoholic 
liver disease (3.4% vs 8.2%, p<0.001), lower prevalence of 
liver cirrhosis (50.8% vs 79.3%, p<0.001), lower number of 
tumors (mean 1.1 vs 1.2, p<0.001), larger size of maximal 
tumor (mean 3.4 cm vs 2.0 cm, p<0.001) and higher level 
of serum AFP (1.4±1.0 log10 ng/mL vs 1.2±0.8 log10 ng/mL, 
p<0.001) and PIVKA-II (1.9±0.7 log10 mAU/mL vs 1.7±0.6 
log10 mAU/mL, p<0.001) (Table 1).
3. Changes in the recurrence rate of HCC during the 
follow-up
During the follow-up period (median, 58.6 months), 
693 patients (46.5%) developed HCC recurrence. After ex-
cluding censored patients at each time points, the cumula-
tive incidence rates of HCC recurrence in each population 
without recurrence were calculated from the time of treat-
ment, and from 1, 2, 3, 4, and 5 years after treatment. 
The cumulative incidences of HCC recurrence were 
0.1%, 4.7%, 10.0% and 14.3% at 3, 6, 9, and 12 months af-
ter treatment, respectively. In 1,229 patients without HCC 
recurrence within 1 year of treatment, the cumulative inci-
dences of recurrence from 1 year after treatment were 5.2%, 
10.5%, 14.1%, and 17.1% at 3, 6, 9, and 12 months, respec-
tively. In 710 patients without HCC recurrence within 3 
years of treatment, the cumulative incidences of recurrence 
from 3 years after treatment were 2.7%, 5.3%, 8.3%, and 
9.9% at 3, 6, 9, and 12 months, respectively. In 417 patients 
without HCC recurrence within 5 years, the cumulative 
incidences of recurrence from 5 years after treatment were 
1.5%, 3.1%, 5.1%, and 6.8% at 3, 6, 9, and 12 months after 5 
years, respectively (Fig. 2).
Although the cumulative incidences of HCC recurrence 
decreased with time progression in both patients with and 
without cirrhosis, the incidences were significantly higher 
in patients with cirrhosis than in those without cirrhosis in 
all time points (p<0.001). Similarly, although the cumula-
tive incidences of HCC recurrence decreased with time 
progression in both patients treated with resection and 
those treated with RFA, the incidences were significantly 
higher in patients treated with RFA than in those treated 
with resection in all time points (p<0.001).
4. Changes in the characteristics of the study 
population with time progression
After excluding censored patients at each time points, 
characteristics of each population without HCC recur-
rence were analyzed at the time of treatment, and at 1, 2, 3, 
4, and 5 years after treatment, respectively. There were no 
changes in the mean age and gender distribution with time 
progression. The mean MELD score decreased from time 
of treatment to 1 year after treatment (7.6 at time of treat-
ment and 7.2 at 1 year after treatment), but there were no 
Table 1. Baseline Characteristics of Patients with HCC Who Were Cured of BCLC Stage A HCC with Surgical Resection or RFA
Characteristics All patients (n=1,491)
Patients treated with resection 
(n=941)
Patients treated with RFA  
(n=550)
p-value
Age, yr 58.6±10.3 57.4±9.9 60.7±10.6 <0.001
Male sex 1,144 (76.7) 747 (79.4) 397 (72.2) 0.001
Etiology <0.001
    HBV 1,152 (77.3) 779 (82.8) 373 (67.8)
    HCV 137 (9.2) 49 (5.2) 88 (16.0)
    Alcohol 77 (5.2) 32 (3.4) 45 (8.2)
    NAFLD 99 (6.6) 67 (7.1) 32 (5.8)
    Other 26 (1.7) 14 (1.5) 12 (2.2)
Liver cirrhosis 914 (61.3) 478 (50.8) 436 (79.3) <0.001
MELD score 7.6±2.2 7.0±1.5 8.6±2.8 <0.001
No. of tumors 1.1±0.4 1.1±0.2 1.2±0.5 <0.001
Size of maximal tumor, cm 2.9±1.8 3.4±2.0 2.0±0.9 <0.001
AFP, log10 ng/mL 1.3±0.9 1.4±1.0 1.2±0.8 <0.001
PIVKA-II, log10 mAU/mL 1.8±0.7 1.9±0.7 1.7±0.6 <0.001
Data are presented as mean±SD or number (%).
HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation; HBV, hepatitis B virus; HCV, hepatitis C virus; 
NAFLD, nonalcoholic fatty liver disease; MELD, Model for End-Stage Liver Disease; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K 
absence or antagonist II.
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significant changes thereafter. The proportion of patients 
with chronic HBV infection (77.3% at the time of treat-
ment and 85.0% at 5 years after treatment) and that of pa-
tients who with resection (63.0% at the time of treatment 
and 78.6% at 5 years after treatment) increased with time 
progression, while the proportion of patients with liver cir-
rhosis decreased with time progression (61.4% at the time 
of treatment and 48.8% at 5 years after treatment) (Table 2).
5. Predictors of HCC recurrence at the time of 
treatment
The results of multivariate and univariate Cox-regres-
sion analyses for predictors of HCC recurrence at each 
time point are presented in Table 3 and Supplementary 
Table 1, respectively. Multivariate analyses revealed that 
combined liver cirrhosis (hazard ratio [HR], 2.252; 95% 
confidence interval [CI], 1.861 to 2.726; p<0.001), treated 
with RFA rather than resection (HR, 1.848; 95% CI, 1.541 
to 2.216; p<0.001), multiple tumors (HR, 1.500; 95% CI, 
1.254 to 1.793; p<0.001), maximal tumor size ≥3 cm (HR, 
1.112; 95% CI, 1.060 to 1.166; p<0.001), higher MELD 
score (HR, 1.038; 95% CI, 1.003 to 1.074; p=0.031), higher 
serum AFP (HR, 1.142; 95% CI, 1.050 to 1.242; p=0.002) 
and higher PIVKA-II (HR, 1.176; 95% CI, 1.048 to 1.319; 
p=0.006) levels were significantly associated with increased 
risk of HCC recurrence from the time of treatment. 
6. Changes in the predictors of HCC recurrence over 
time
After excluding censored patients at each time points, 
variables collected at the time of treatment were assessed 
for their prognostic implications with respect to HCC 
recurrence from 1, 2, 3, 4, and 5 years after treatment, re-
spectively (Table 3, Supplementary Table 1).
On multivariate analysis of patients without HCC recur-
rence within 1 year of treatment, combined liver cirrhosis 
(HR, 2.404; 95% CI, 1.912 to 3.024; p<0.001), treated with 
RFA rather than resection (HR, 1.705; 95% CI, 1.395 to 
2.084; p<0.001), multiple tumors (HR, 1.328; 95% CI, 1.050 
to 1.678; p=0.018), and higher MELD score (HR, 1.068; 
95% CI, 1.025 to 1.113; p=0.002) at time of treatment were 
significantly associated with increased risk of HCC recur-
rence from 1 year after treatment. Multivariate analysis of 
predictors of HCC recurrence from 2 years after treatment 
showed similar results with those of HCC recurrence from 
1 year after treatment (Table 3).
In patients without HCC recurrence within 3 years of 
treatment, older age (HR, 1.020; 95% CI, 1.002 to 1.038; 
p=0.026), combined liver cirrhosis (HR, 3.136; 95% CI, 
2.066 to 4.759; p<0.001), and treated with RFA rather than 
resection (HR, 1.872; 95% CI, 1.290 to 2.717; p=0.001) 
were significantly associated with an increased risk of HCC 
recurrence from 3 years after treatment. Combined liver 
cirrhosis (HR, 2.846; 95% CI, 1.692 to 4.787; p<0.001) and 
treated with RFA rather than resection (HR, 1.651; 95% CI, 
1.011 to 2.697; p=0.045) were independent predictors for 
HCC recurrence from 4 years. Older age (HR, 1.042; 95% 
CI, 1.005 to 1.079; p=0.024) and combined liver cirrhosis 
(HR, 3.167; 95% CI, 1.445 to 6.891; p=0.004) were inde-
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Fig. 2. One-year cumulative inci-
dence of hepatocellular carcinoma 
(HCC) recurrence from the time of 
curative treatment and from 1, 2, 3, 
4, and 5 years after treatment.
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DISCUSSION
The changes of pattern and independent predictors 
of HCC recurrence after curative treatment with time 
progression arouse the confusion in differentiation of 
early and late recurrence and thereby, the establishment 
of surveillance strategy for HCC recurrence. In our large 
multicenter retrospective cohort study, we enrolled pa-
tients with first-time diagnosis of BCLC A HCC and who 
were completely cured with surgical resection or RFA. The 
cumulative incidence rates of HCC recurrence decreased 
gradually as time progressed. Liver cirrhosis and treated 
with RFA rather than resection were independently associ-
ated with increased risk of HCC recurrence from almost 
all time points, whereas multiple tumors, maximal tumor 
size ≥3 cm, and higher MELD score were independently 
associated with increased risk of HCC recurrence only 
from within 2 years after curative treatment.
Our study comes with several unique strengths and 
clinical implications. First, we included the largest number 
(n=1,491) of patients to our knowledge. Previous studies 
evaluating the change of HCC recurrence pattern have 
assessed a maximum of 816 patients.12,14,15,17 Besides, in 
contrast to other studies that only included patients treated 
with surgical resection,12,14,15,17,28 we recruited patients treat-
ed with both surgical resection and RFA. The diversity and 
large size of this study population enabled us to effectively 
compare the changes in recurrence patterns and indepen-
dent predictors of HCC recurrence.
Further, the cumulative incidence rates of HCC recur-
rence gradually decreased with time. This result suggests 
that the surveillance interval could be gradually prolonged 
as time progression. However, we found significant dif-
ferences in incidence rates of HCC recurrence between 
patients with and without cirrhosis, and between patients 
treated with surgical resection and RFA (all p<0.001). 
These differences indicate that the interval periods should 
be adjusted to each patient depending on the cirrhosis and 
type of treatment.
This study clearly showed that tumor-related factors 
were independently associated with increased risk of HCC 
recurrence from only within 2 years of treatment. Multiple 
tumors and maximal tumor size ≥3 cm were independent-
ly associated with the increased risk of HCC recurrence 
from the time within 2 years after treatment. Serum AFP 
and PIVKA-II levels were independently associated with 
the increased risk of HCC only from the time of treatment. 
Bearing in mind the different pathogenesis of early and 
late recurrence, it is conceivable that tumor factors do not 
affect the development of late recurrence.
The difference in predictors for early and late recur-
rence have been evaluated in several previous studies. 
However, classical concept of liver-related and tumor-
related factors have not been clearly revealed than we have 
expected. Imamura et al.12 showed that multiple tumors 
and gross tumor classification were significantly associated 
with late recurrence in patients treated with surgical resec-
tion. Wu et al.14 also suggested that multinodularity of tu-
mor was significant predictor for both early and late recur-
rence in patients with HBV-related HCC. This discrepancy 
could be explained by the exclusion of presence of liver 
cirrhosis from the analysis variables. Also, it was surprising 
that patients without cirrhosis have shown to have similar 
prognosis with that of patients with cirrhosis.14 Cheng et 
al.17 indicated that AFP >400 ug/L was independently as-
sociated with late recurrence in patients with solitary HCC 
and treated with partial hepatectomy, suggesting that these 
results were possibly due to the association of cirrhosis 
and elevated serum AFP level. However, this suggestion 
does not seem to be persuasive, because liver cirrhosis 
was the other independent predictor of late recurrence. 
Though many previous studies12,14,17 indicated the tumor-
related factors as significant predictors for late recurrence, 
it seems that these disparities have been arisen from the 
heterogeneity of HCC stage in enrolled patients. The clas-
sical concept for liver and tumor-related factors could be 
ideally elucidated in early stage HCC, because advanced 
stage HCC may not be completely removed after successful 
curative treatment, and microscopic intrahepatic metasta-
ses often remain. Therefore, we only included patients with 
BCLC stage A HCC to clearly prove this classical concept.
For all the time points analyzed after treatment, liver 
cirrhosis emerged as a potent independent predictor of 
HCC recurrence (all p<0.05). These results were consis-
tent with the previously mentioned studies.17,28 In fact, 
late recurrence is specifically considered to be due to the 
development of second primary HCC after treatment at 
primary sites, and this field effect plays a critical role in 
hepatocarcinogenesis.29 Therefore, it can be concluded that 
in patients with liver cirrhosis, the risk of second primary 
HCC development remains high even after successive cu-
rative treatment. 
We also found that treatment with RFA was an inde-
pendent predictor of HCC recurrence form almost all time 
points after treatment. Because the type of treatment is 
decided based on both tumor and liver disease related fac-
tors, it could reflect both tumor- and liver disease-related 
factors. Patients advised to undergo RFA tend to have more 
advanced stages of liver dysfunction, older age and have 
more comorbidities than those who are advised to undergo 
surgical resection. These features might cause increased in-
cidence of both early and late recurrence in patients treated 
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with RFA rather than in patients treated with resection. 
Finally, when considering the time point when the 
tumor-related factors lose their prognostic implication for 
HCC recurrence, 2 years after treatment may be used as 
the period defining early and late recurrence of HCC, con-
sistent with the classical belief.10,11 Therefore, it is accept-
able that the duration with sustained clinical implication of 
tumor-related factors could be the optimal cutoff point for 
differentiating early and late recurrence of HCC. Thus, this 
study has made an important clinical contribution towards 
defining the period of early recurrence as 2 years after 
treatment, because there has been no sufficient evidence 
yet.
There are several limitations and issues that remain 
unaddressed. First, the retrospective design of our study 
allows for potential selection bias and lead–time bias. 
Second, a large proportion of patients treated with RFA 
suffered from early recurrence or death, leaving only 88 
patients treated with RFA for analysis at 5 years after treat-
ment. Therefore, the prognostic significance of RFA would 
not be observed in recurrence from 5 years after treatment. 
Third, the MELD score, which represents the degree of liv-
er dysfunction, was significantly associated only with early 
recurrence in this study. This disparity could be explained 
by the earlier death of patients with higher MELD score. 
Lastly, majority of patients had HBV infection (77.3%). It 
has been well known that 62.2% of HCC patients in Korea 
have HBV infection,30 and this could be important limita-
tion of this study. Further studies in different population 
would be needed for general application of this result.
In conclusion, we demonstrated a gradual decrease in 
the incidence rates of HCC recurrence after curative treat-
ment in patients with BCLC A HCC. Tumor-related factors 
were independently associated with increased risk of HCC 
recurrence from within 2 years after treatment. Therefore, 
the period of 2 years after curative treatment may be used 
to differentiate early and late recurrence of HCC.
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